LungFX Device
Lung Bioengineering, Inc. · Decision date Oct 16, 2026
What did the FDA approve?
The FDA database entry P240033/S002 records approval of a post-approval study (PAS) protocol for the LungFX device, submitted on the normal 180 day track with no user fee. The stated purpose is to comply with conditions of approval in the original P240033 order; this supplement does not re-approve the whole system or add an indication. The listed device category describes the original scope: a normothermic preservation system for transplantation of initially unacceptable donor lungs, with product code PHO and applicant Lung Bioengineering, Inc.
The entry does not state the protocol's study design, endpoints, sample size, follow-up duration, or the specific approval conditions it addresses. It also records no safety or effectiveness findings, and the compliance statement is not independent evidence of clinical benefit. The specialty fields list Gastroenterology, Urology, which the supplied text does not explain relative to the lung preservation scope.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240033.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 16, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240033/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Lung Bioengineering, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Lung Bioengineering, Inc.
- Product code
- PHO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240033 · Original PMA
LungFX device
P240033/S002 received
Application receipt date recorded by FDA.
P240033/S001 · Related supplement
LungFX Device
P240033/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P240033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LungFX deviceP240033 | Lung Bioengineering, Inc. | PMA approval | Jun 22, 2026 | FDA |
LungFX DeviceP240033/S001 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
TorEx Lung Perfusion SystemP250025 | Traferox Technologies, Inc. | PMA approval | Jul 15, 2026 | FDA |
| Xvivo Perfusion, Inc. | PMA approval | Apr 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lung Bioengineering, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Lb1 Bldg., 1015 Spring St., Silver Spring, MD, 20910
Sources and methodology
- Original FDA record: P240033/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




